Take Solutions Ltd
About
TAKE Solutions Limited is a Chennai-based contract research organisation (CRO) that provides end-to-end support to pharmaceutical, biotechnology and medical device companies worldwide. Originally founded as a supply chain management solutions company, TAKE pivoted to the life sciences sector following the 2008 global financial crisis, recognising the industry’s recession resistant potential. Under the brand Navitas Life Sciences, the company is primarily involved in the fields of clinical research, generics development, regulatory affairs, and pharmacovigilance. TAKE also offers services like clinical trials, regulatory compliance, and postmarketing safety. North America accounts for 2/3rds of the company’s revenue, making it TAKE’s largest market, followed by the Asia-Pacific Region.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 67 -66.0% | 198 -70.6% | 672 -14.8% | 788 -64.8% | 2239 9.3% | 2050 28.6% | 1594 17.4% | 1357 29.2% | 1051 42.3% | 739 -10.1% | 822 -2.0% | 839 16.7% | 719 42.0% | 506 38.2% | 366 6.7% | 343 - |
| Net Operating Income (INR Cr) | 66 -65.30% | 189 -71.14% | 655 -15.35% | 774 -65.02% | 2213 8.53% | 2039 28.46% | 1587 18.05% | 1345 30.52% | 1030 41.03% | 730 -10.44% | 816 -1.97% | 832 18.23% | 704 40.65% | 500 42.22% | 352 4.87% | 335 14.13% |
| Profit (INR Cr) | -120 - | -100 - | -782 - | -452 - | -12 - | 177 10.5% | 160 12.2% | 143 19.6% | 120 71.2% | 70 20.5% | 58 -27.0% | 79 -7.1% | 86 22.3% | 70 115.8% | 32 -38.7% | 53 - |
| Assets (INR Cr) | 29 -81.1% | 156 -40.0% | 260 -84.5% | 1673 -23.4% | 2185 9.1% | 2003 20.4% | 1663 38.3% | 1202 18.0% | 1019 27.7% | 798 8.8% | 733 9.6% | 669 15.9% | 577 21.8% | 474 12.9% | 420 2.5% | 410 - |
| Net Worth (INR Cr) | -9 -108.2% | 109 -40.0% | 181 -83.9% | 1125 -28.6% | 1575 3.8% | 1518 14.3% | 1328 45.8% | 911 44.3% | 631 20.4% | 524 11.6% | 470 11.8% | 420 23.0% | 342 34.3% | 255 -30.4% | 366 -0.7% | 368 27.5% |
| Employee Cost (INR Cr) | 15 -68.8% | 48 -84.5% | 309 -34.7% | 474 -34.1% | 719 21.5% | 592 32.4% | 447 15.4% | 387 37.4% | 282 34.3% | 210 -7.4% | 227 0.7% | 225 23.6% | 182 31.0% | 139 -1.9% | 142 27.9% | 111 - |
| Interest Cost (INR Cr) | 5 | 7 | 29 | 37 | 41 | 25 | 21 | 23 | 15 | 13 | 14 | 14 | 18 | 8 | 4 | 2 |
| Cash & Bank Balance (INR Cr) | 1 | 11 | 30 | 39 | 45 | 70 | 341 | 110 | 128 | 124 | 77 | 76 | 60 | 46 | 48 | 54 |
| Total Debt (INR Cr) | 37 | 46 | 59 | 514 | 553 | 474 | 323 | 237 | 336 | 209 | 207 | 196 | 193 | 185 | 34 | 24 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | - | - | - | - | - | 8.7% | 10.1% | 10.5% | 11.4% | 9.5% | 7.1% | 9.5% | 11.9% | 13.8% | 8.9% | 15.4% |
| Profit As % Of Assets | - | - | - | - | - | 8.9% | 9.7% | 11.9% | 11.7% | 8.8% | 7.9% | 11.9% | 14.8% | 14.8% | 7.7% | 12.9% |
| Profit As % Of Networth | - | - | - | - | - | 11.7% | 12.1% | 15.7% | 19.0% | 13.3% | 12.3% | 18.9% | 25.0% | 27.5% | 8.9% | 14.4% |
| Interest Cost to EBITDA % | - | - | - | - | 24.4% | 6.5% | 6.8% | 8.6% | 6.9% | 8.5% | 9.4% | 8.9% | 12.6% | 7.5% | 12.5% | 3.6% |
| Debt to Equity Ratio | - | 0.43 | 0.32 | 0.46 | 0.35 | 0.31 | 0.24 | 0.26 | 0.53 | 0.40 | 0.44 | 0.47 | 0.56 | 0.73 | 0.09 | 0.06 |
| RONW | - | - | - | - | - | 12.5% | 14.3% | 19.0% | 18.9% | 16.1% | 13.9% | 22.3% | 28.5% | 22.0% | 9.5% | 16.0% |
| ROCE | 0.0% | 0.0% | 0.0% | -9.2% | 1.4% | 13.2% | 14.8% | 17.6% | 16.4% | 13.8% | 11.7% | 20.3% | 25.4% | 19.6% | 10.8% | 16.7% |